Brind.

Legend Biotech reported record CARVYKTI sales driving revenue growth, coinciding with an FDA label update to reduce monitoring.

1 report, 1 independent Updated Aug 12

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Legend Biotech FDA

Keep exploring

The entities involved

Legend Biotech
Biotech company

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 12GuruFocus.comLegend Biotech Corp (LEGN) Q2 2025 Earnings Call Highlights: Record CARVYKTI Sales and ... CARVYKTI Net Trade Sales: $439 million, a 136% increase year over year. Total Revenues: $255 million, driven